- 阻害剤
- 研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- 化合物ライブラリー
- 抗体
- 新製品
- お問い合わせ
All New Products Listed Chronologically
| 製品コード | 製品名称 | 製品説明 | 添加時期 |
|---|---|---|---|
| F3954 | α 1,2 Mannosidase IA/MAN1A1 Antibody [H3N23] | Dec 12 2025 | |
| F3955 | RhoGDI Antibody [H2N24] | Dec 12 2025 | |
| F4093 | ATPIF1 Antibody [P8F22] | Dec 12 2025 | |
| F4427 | GDF-15 Antibody [G11L21] | Dec 12 2025 | |
| F4429 | Uteroglobin/CC10 Antibody [H18P18] | Dec 12 2025 | |
| F4432 | NF-YA Antibody [K24M4] | Dec 12 2025 | |
| F4483 | PSR Antibody [F14P18] | Dec 12 2025 | |
| F4585 | Syntaxin-4 Antibody [C14K1] | Dec 12 2025 | |
| F4603 | Desmin Antibody [G12C10] | Dec 12 2025 | |
| F4607 | MLKL Antibody [H6A20] | Dec 12 2025 | |
| F4609 | GSK-3-α Antibody [G23H20] | Dec 12 2025 | |
| F4624 | TIMP2 Antibody [L18F24] | Dec 12 2025 | |
| F4636 | EED Antibody [E19A22] | Dec 12 2025 | |
| F4664 | EPAC2 Antibody [G13N1] | Dec 12 2025 | |
| F4670 | Keratin 18 Antibody [M2J10] | Dec 12 2025 | |
| F4782 | MTA1 Antibody [F4J14] | Dec 12 2025 | |
| F4793 | Interferon regulatory factor 9/IRF-9 Antibody [N16H20] | Dec 12 2025 | |
| F4794 | CBX1/HP1β Antibody [L5A14] | Dec 12 2025 | |
| F4795 | Fibronectin Antibody [C18P7] | Dec 12 2025 | |
| F2691 | CHOP Antibody [C21N8] | CHOP,DDIT3,DDIT3/GADD153/CHOP,GADD153/CHOP | Dec 12 2025 |
| F4438 | GPX1/2 Antibody [L20K22] | Dec 12 2025 | |
| F0280 | EGR1 Antibody [N15L8] | Dec 12 2025 | |
| F0394 | Phospho-Bad (Ser136) Antibody [K15E21] | Dec 12 2025 | |
| F0403 | Phospho-TrkA (Tyr674/675)/TrkB (Tyr706/707) Antibody [K13K11] | Dec 12 2025 | |
| F0473 | Caspase-7 Antibody [H18L1] | Dec 12 2025 | |
| F0430 | EGF Receptor (E746-A750del Specific) Antibody [L24P14] | Dec 12 2025 | |
| F0496 | Phospho-GSK-3α/β (Ser21/9) Antibody [N3H2] | Dec 12 2025 | |
| F1133 | NEDD8 Antibody [D22F6] | Dec 12 2025 | |
| F1291 | JAK3 Antibody [F8D8] | Dec 12 2025 | |
| F1374 | HSL Antibody [M23F5] | Hormone sensitive lipase/HSL,HSL | Dec 12 2025 |
| F1507 | CA9 Antibody [J19A24] | CA9,Carbonic Anhydrase 9/CA9,Carbonic Anhydrase IX/CA9 | Dec 12 2025 |
| F1545 | Sp7/Osterix Antibody [J12J9] | OSX,Sp7 / Osterix | Dec 12 2025 |
| F0861 | TCF11/NRF1 Antibody [F22N18] | Dec 12 2025 | |
| F1506 | Artemis Antibody [H20J21] | Dec 12 2025 | |
| F1158 | Human Nuclear Antigen Antibody [M1M8] | Dec 12 2025 | |
| F1536 | CD11b + CD11c Antibody [C8C21] | CD11b + CD11c,CD11b/c | Dec 12 2025 |
| F1643 | Glutathione Antibody [A11G7] | Dec 12 2025 | |
| F2030 | 5-hydroxymethylcytosine Antibody [B13H23] | Dec 12 2025 | |
| F2031 | VSV-G tag Antibody [N12B16] | VSV Glycoprotein,VSV-G tag | Dec 12 2025 |
| F2048 | Acetyl-p53 (Lys373) Antibody [J7D9] | Dec 12 2025 | |
| F1926 | α-adaptin A Antibody [D21J17] | alpha Adaptin,alpha-Adaptin,α-Adaptin 1/2 | Dec 12 2025 |
| F2201 | Phospho-SHP2 (Tyr542) Antibody [J17K6] | Phospho-SHP-2 (Tyr542),SHP2 (phospho Y542) | Dec 12 2025 |
| F2223 | ATP synthase C Antibody [E17F23] | Dec 12 2025 | |
| F2358 | Phospho-STAT1 (Ser727) Antibody [F23C16] | Phospho-Stat1 (Ser727),STAT1 (phospho S727) | Dec 12 2025 |
| F2643 | Lipin 1 Antibody [G22A22] | Dec 12 2025 | |
| F2483 | Somatostatin Receptor 1/SSTR1 Antibody [F9M21] | Dec 12 2025 | |
| F2238 | Influenza A Virus M2 Protein Antibody [L21L24] | Influenza A M2,Influenza A Virus M2 Protein | Dec 12 2025 |
| F3018 | IFN-γ Antibody [A4P20] | IFN-γ,Interferon gamma | Dec 12 2025 |
| F3039 | Acetyl-CoA Carboxylase 2 Antibody [E20M20] | Dec 12 2025 | |
| F3034 | TIM-3 Antibody [N19P14] | TIM 3,TIM-3 | Dec 12 2025 |
| F2530 | ZO1 tight junction protein Antibody [A24G22] | Tight Junction Protein 1,ZO-1,ZO1 tight junction protein | Dec 12 2025 |
| F3114 | Involucrin Antibody [B10D23] | Dec 12 2025 | |
| F2353 | VEGFB Antibody [E11E24] | VEGFB,VEGF-B | Dec 12 2025 |
| F2035 | IL-33 Antibody [A21K18] | Dec 12 2025 | |
| F2948 | smooth muscle Myosin heavy chain 11 Antibody [J22F5] | MYH11,Myosin (Smooth),smooth muscle Myosin heavy chain 11 | Dec 12 2025 |
| F1564 | Mucin 5AC Antibody [L15D9] | Blood Group Lewis b,MUC5AC,Mucin 5AC,Mucin 5AC/MUC5AC,Mucin Gastric,Mucin MUC5AC | Dec 12 2025 |
| F2693 | Desmoglein 1 Antibody [L24P16] | Desmoglein 1,Desmoglein 1/DSG1 | Dec 12 2025 |
| F2701 | Thymine Dimer Antibody [E15K19] | Dec 12 2025 | |
| F2741 | uPA Antibody [F9E24] | uPA,Urokinase | Dec 12 2025 |
| F2742 | Transferrin Antibody [F4N15] | Dec 12 2025 | |
| F2743 | Ferritin Light Chain Antibody [N23F20] | Ferritin Light Chain,FTL | Dec 12 2025 |
| F2963 | CaMKI Antibody [G24K20] | Dec 12 2025 | |
| F2977 | KIF4A/KIF4 Antibody [N7K8] | Dec 12 2025 | |
| F0312 | ULK1 Antibody [A14P9] | Atg1/ULK1,ULK1 | Dec 12 2025 |
| F0406 | Phospho-cdc25C (Ser216) Antibody [D12E13] | Cdc25C (phospho S216),Phospho-cdc25C (Ser216) | Dec 12 2025 |
| F3319 | Phospho-Syk (Tyr323) Antibody [G1N3] | Dec 12 2025 | |
| F3193 | PTP1B Antibody [B2E10] | Dec 12 2025 | |
| F3421 | PF4 Antibody [L7F2] | CXCL4/PF4,PF4 | Dec 12 2025 |
| F3241 | Phospho-β Catenin (Ser675) Antibody [D16B23] | Dec 12 2025 | |
| F3588 | Myosin Light Chain 2 Antibody [C23E15] | MYL9,Myosin Light Chain 2 | Dec 12 2025 |
| F3669 | Hsp22/HSPB8 Antibody [E11C19] | Hsp22/HSPB8,HSPB8/HSP22 | Dec 12 2025 |
| F3306 | Phospho-Nephrin (Tyr1217) Antibody [L5D2] | Dec 12 2025 | |
| F3428 | Chromogranin A Antibody [C10M7] | CHGA,Chr-A,Chromogranin A | Dec 12 2025 |
| F3439 | RPL10A Antibody [D11A13] | Ribosomal Protein L10a,RPL10A | Dec 12 2025 |
| F3463 | SESN1 Antibody [C3P2] | Dec 12 2025 | |
| F3646 | Phospho-Nephrin (Tyr1176 + Tyr1193) Antibody [D21M18] | Dec 12 2025 | |
| F3732 | Influenza A virus (H5N1/HA1) Antibody [L10F5] | Dec 12 2025 | |
| F3218 | 5T4 Antibody [J8G16] | 5T4,TPBG/5T4 | Dec 12 2025 |
| F3249 | Cyclin D2 Antibody [F5H24] | Dec 12 2025 | |
| F3292 | PCB Antibody [K5L1] | PCB,Pyruvate Carboxylase | Dec 12 2025 |
| F3647 | Phospho-EGFR (Tyr992) Antibody [F20E14] | EGFR (phospho Y992),Phospho-EGF Receptor (Tyr992) | Dec 12 2025 |
| F3045 | Phospho-PKCδ (Thr505) Antibody [P3G5] | Dec 12 2025 | |
| F3783 | Phospho-JAK1 (Tyr1034 + Tyr1035) Antibody [F22D15] | JAK1 (phospho Y1034 + Y1035),Phospho-Jak1(Tyr1034/1035) | Dec 12 2025 |
| F4136 | Phospho-Src Family (Tyr416) Antibody [D13C8] | Dec 12 2025 | |
| F4118 | LTβR Antibody [H12L6] | Dec 12 2025 | |
| F4127 | ULK1 Antibody [K18A5] | Dec 12 2025 | |
| F4155 | Phospho-HER2/ErbB2 (Tyr1221/1222) Antibody [N18K6] | Dec 12 2025 | |
| F4390 | Keratin K3/K76 Antibody [A4J6] | Dec 12 2025 | |
| F4985 | Cleaved PARP (Asp214) Antibody [C3D4] | Dec 12 2025 | |
| F4202 | BRD4 Antibody [E1J10] | Dec 12 2025 | |
| F4586 | Gab1 Antibody [M2K23] | Dec 12 2025 | |
| F4192 | Caspase-1 Antibody [C2H20] | Dec 12 2025 | |
| F4203 | ATF-6 Antibody [G8H4] | Dec 12 2025 | |
| F4340 | KCC2 Antibody [K20G10] | Dec 12 2025 | |
| F4415 | NLRP3 Antibody [E14M24] | Dec 12 2025 | |
| F4734 | p73 Antibody [J24D9] | Dec 12 2025 | |
| F4779 | Mannose Receptor Antibody [E13A19] | Dec 12 2025 | |
| F4189 | HER3/ErbB3 Antibody [N12M8] | Dec 12 2025 | |
| F4648 | USP18 Antibody [A22C11] | Dec 12 2025 | |
| F4539 | Human COMMD1 Antibody [B20N14] | Dec 12 2025 | |
| F4602 | Clathrin Heavy Chain Antibody [N1G10] | Dec 12 2025 | |
| F4963 | FUT8 Antibody [P15J12] | Dec 12 2025 | |
| F5042 | Upf1 Antibody [E5D18] | Dec 12 2025 | |
| F2813 | RAMP1 Antibody [N11L21] | Dec 12 2025 | |
| F2856 | APG5L/ATG5 Antibody [K12K17] | APG5/ATG5,APG5L/ATG5,Atg5 | Dec 12 2025 |
| F2860 | Phospho-NAK/TBK1 (Ser172) Antibody [G18L12] | NAK/TBK1 (phospho S172),Phospho-TBK1/NAK (Ser172) | Dec 12 2025 |
| F4175 | K63-linkage Specific Polyubiquitin Antibody [P10B21] | Dec 12 2025 | |
| F5003 | CD86 Antibody [M17L10] | Dec 12 2025 | |
| F5025 | POLR1A Antibody [E1L22] | Dec 12 2025 | |
| F5059 | SOD1 Antibody [L21J5] | Dec 12 2025 | |
| F9003 | UBQLN1 Antibody [M14H23] | Dec 12 2025 | |
| F9446 | ApoA5 Antibody [H10J23] | Dec 12 2025 | |
| F4919 | Myc tag Antibody [A14H15] | Dec 12 2025 | |
| F2686 | Acetyl-α-Tubulin (Lys40) Antibody [F22D16] | acetyl-alpha tubulin,Acetyl-alpha Tubulin (Lys40),Acetylated Tubulin,Acetyl-α-Tubulin (Lys40),alpha Tubulin (acetyl K40),alpha Tubulin acetyl K40,Tubulin, Acetylated | Dec 12 2025 |
| F3951 | UQCRH Antibody [A9L21] | Dec 12 2025 | |
| F3953 | Phospho-Synapsin I (Ser553) Antibody [F18C24] | Dec 12 2025 | |
| E6646 | BMS-986260 | BMS - 986260は、免疫腫瘍学的薬剤であり、強力で選択的かつ経口活性のあるTGFβR1阻害剤（IC50 = 1.6 nM）です。BMS - 986260は、そのアイソザイムであるTGFβR2に対して、また調べた200種以上のキナーゼのパネルにおいても、TGFβR1に対して極めて高い選択性を示します。BMS - 986260は、MINKおよびNHLF細胞株におけるTGFβ介在性のpSMAD2/3の核移行をそれぞれ350 nMおよび190 nMのIC50で阻害します。 | Dec 09 2025 |
| E6639 | Auceliciclib (AU3-14,Ulecaciclib ) | ウレカシクリブは、サイクリン依存性キナーゼ（CDK）の経口活性型阻害剤であり、それぞれのKi値は、0.62 μM（CDK2/サイクリンA）、0.2 nM（CDK4/サイクリンD1）、3 nM（CDK6/サイクリンD3）、および0.63 μM（CDK7/サイクリンH）です。ウレカシクリブは血液脳関門を通過することができ、良好な薬物動態特性を持っています。 | Dec 04 2025 |
| P1231 | Mazdutide (IBI362, LY330567) | マズデュチド（IBI - 362；LY - 3305677）は、長時間作用型の合成オキシントモジュリン類似体です。マズデュチドはまた、グルカゴン様ペプチド受容体（GLP - 1R）とグルカゴン受容体（GCGR）の共作動薬でもあります。マズデュチドは、ヒトおよびマウスのGCGR（それぞれKi：17.7 nMおよび15.9 nM）とGLP - 1R（それぞれKi：28.6 nMおよび25.1 nM）に結合し、マウス膵島からのインスリン分泌を刺激します（EC50：5.2 nM）。マズデュチドは、肥満症および2型糖尿病（T2D）の研究に使用されます。 | Dec 04 2025 |
| E6643 | SS-3091 | SS - 3091はパンKRas阻害剤です。SS - 3091はKRasの相互作用界面に結合し、ARaf/KRas複合体を不安定化させ、それにより下流のシグナル伝達に影響を与えます。SS - 3091は、様々な癌細胞におけるKRas G12D、G12C、G12V、およびG12S変異体に対して有意な抗癌および抗増殖活性を有します。 | Dec 04 2025 |
| E5927 | Mito-LND (Mito-Lonidamine) | ミト-LND（ミト-ロニダミン）は、経口活性を持ち、ミトコンドリアを標的とする酸化的リン酸化（OXPHOS）の阻害剤です。ミト-LNDは、ミトコンドリアのエネルギー代謝を阻害し、活性酸素種の生成を促進し、肺癌細胞においてオートファジー性細胞死を誘導します。 | Dec 04 2025 |
| E6511 | ADT-1004 | ADT - 1004はRASの阻害剤です。ADT - 1004はRas介在性疾患の研究において検討することができます。 | Dec 04 2025 |
| E6526 | MCB-294 | MCB - 294は、NRASおよびHRASよりも選択的にKRASを阻害する二状態型パンKRAS阻害剤です。MCB - 294は、KRASの活性型（GTP結合型）と不活性型（GDP結合型）の両方に結合することができ、それぞれの解離定数（Kd）は約1 pMと10 nMです。MCB - 294は、G12D、G12C、G12V、G12S、G13Dおよび野生型KRASを発現するhTERT - HPNE細胞の増殖を広範囲に阻害し、IC50は約700 nMです。MCB - 294は、KRAS変異腫瘍において不可逆的なアポトーシスを誘導します。MCB - 294は、KRASG12C阻害剤耐性癌細胞を効果的に抑制し、腫瘍免疫微小環境を改変します。MCB - 294は、膵臓癌、結腸直腸癌および肺癌の研究に使用することができます。 | Dec 04 2025 |
| E5936 | FT895 | FT895は、IC50が3 nMの強力かつ選択的なHDAC11阻害剤です。 | Dec 04 2025 |
| E6647 | Bireociclib (XZP-3287,CDK4/6-IN-2) | CDK4/6 - IN - 2は、特許US20180000819A1、化合物1から抽出された強力なCDK4およびCDK6阻害剤であり、CDK4およびCDK6に対するIC50はそれぞれ2.7 nMおよび16 nMである。 | Dec 04 2025 |
| E6638 | VS-7375 (GFH375) | VS-7375 (GFH375) is an oral small-molecule inhibitor that selectively targets KRAS G12D in both its active (GTP-bound) and inactive (GDP-bound) forms. This dual-state inhibition results in stronger tumor suppression compared to single-state inhibitors. It exhibits potent anti-proliferative and anti-tumor effects in KRAS G12D-mutant models, including an intracranial GP2D tumor model. | Dec 04 2025 |
| E6517 | PKN1 | PKN1/2 - IN - 1は、強力な細胞透過剤であり、選択的なPKN1/2阻害剤です。PKN1およびPKN2に対するIC50値はそれぞれ16 nMおよび210 nMで、Ki値はそれぞれ8 nMおよび108 nMです。PKN1/2 - IN - 1は、NanoBRETアッセイにおいて強力な細胞内PKN2結合能を示します（IC50 = 2.1 μM）。PKN1/2 - IN - 1は、腫瘍細胞の遊走などの生理的過程を研究するために使用できます。 | Dec 02 2025 |
| E6521 | HRS‑5346 | Lp(a)-IN-5（化合物A）は、経口投与可能なリポタンパク質(a)（Lp(a)）阻害剤です。Lp(a)-IN-5は、IC50値が0.41 nMでアポリポタンパク質(a)（Apo(a)）とアポリポタンパク質B（ApoB）のタンパク質のアセンブリを阻害します。Lp(a)-IN-5は、血漿中のLp(a)レベルの上昇に関連する疾患、例えば心血管疾患の研究に有望です。 | Dec 02 2025 |
| E6578 | AS1708727 | AS1708727は経口活性型のFoxo1阻害剤で、G6PaseおよびPEPCKに対するEC50値はそれぞれ0.33 μMおよび0.59 μMである。 | Dec 02 2025 |
| E6498 | Atebimetinib (IMM-1-104) | アテビメチニブはMEKチロシンキナーゼの阻害剤であり、抗腫瘍活性を示す。 | Dec 02 2025 |
| E6636 | DY268 | DY268はファルネソイドX受容体（FXR）アンタゴニスト（IC50 = 7.5 nM）です。細胞ベースのアッセイにおいて、IC50値468 nMでFXRの転写活性化を阻害します。DY268は薬物性肝障害（DILI）の研究に使用できます。 | Nov 25 2025 |
| E6634 | Thiethylperazine | チエチルペラジンは、フェノチアジン誘導体であり、経口投与で活性を示し、強力なドーパミンD2受容体およびヒスタミンH1受容体拮抗薬です。チエチルペラジンはまた、マウスにおけるアミロイド-β（Aβ）負荷を低減する選択的なABCC1活性化薬でもあります。チエチルペラジンは、抗嘔吐、抗精神病および抗菌作用を有します。 | Nov 25 2025 |
| E6565 | Ofirnoflastum | オフィルノフラスタム（オフィルノフラスト）はセリン/トレオニン - タンパク質キナーゼNek7阻害剤で、抗炎症効果を有します。 | Nov 24 2025 |
| E6572 | AD1058 | AD1058は、経口活性があり、選択的で、血液脳関門を透過できるATRの阻害剤です（IC50: 1.6 nM）。AD1058は、腫瘍細胞の増殖を阻害し、細胞周期を停止させ、アポトーシスを促進することにより、抗癌活性を示します。AD1058は、進行がんや脳転移の研究に適しています。 | Nov 24 2025 |
| E6588 | LY3509754 | LY3509754（IL - 17Aインヒビター1）はIL - 17Aインヒビターであり、アルファリサアッセイおよびHT - 29細胞におけるIC50値はそれぞれ<9.45 nMおよび9.3 nMである。 | Nov 24 2025 |
| E4617 | Gly-β-MCA | 胆汁酸であるGly - β - MCAは、強力で安定的な、腸選択的かつ経口で生物学的活性を有するファルネソイドX受容体（FXR）阻害剤であり、代謝障害の治療薬の候補となり得る。 | Nov 21 2025 |
| E1219 | CSN5i-3 | CSN5i - 3は、CSN5/Jab1の強力で選択的かつ経口投与可能な阻害剤であり、IC50値5.8 nMでCSN触媒によるCul1のデネディル化を阻害します。 | Nov 21 2025 |
| E8318 | T6167923 | T6167923は、MyD88依存的シグナル伝達経路の選択的阻害剤です。T6167923は、MyD88のToll/IL1受容体（TIR）ドメインに直接結合し、MyD88のホモ二量体形成を阻害します。T6167923は、NF-κBによって駆動される黄色ブドウ球菌エンテロトキシンAP（SEAP）活性を阻害し、IFN-γ、IL-1β、IL-6、TNF-αに対するIC50値がそれぞれ2.7μM、2.9μM、2.66μM、2.66μMで抗炎症活性を向上させます。 | Nov 21 2025 |
| E1892 | FM4-64 | FM4 - 64は非常に脂溶性で水溶性のスチレン染料で、細胞膜および内膜小器官に特異的に結合して蛍光を発することができます。FM4 - 64はエンドサイトーシスおよびエキソサイトーシスの膜構造マーカーとして広く使用されています。 | Nov 21 2025 |
| E1162 | GLPG0974 | GLPG0974は、IC50が9 nMの遊離脂肪酸受容体-2（FFA2/GPR43）拮抗薬です。 | Nov 21 2025 |
| E1888 | NIM811 ((Melle-4)cyclosporin) | NIM811（(Melle - 4)シクロスポリン；SDZ NIM811）は、経口投与可能なミトコンドリア透過性転移とサイクロフィリンの二重阻害剤であり、C型肝炎ウイルス（HCV）に対して強力なin vitro活性を示します。 | Nov 21 2025 |
| E4757 | Setidegrasib (ASP3082) | Setidegrasib (ASP3082; KRAS G12D inhibitor 17) is a PROTAC degrader targeting KRAS(G12D) with a DC50 of 38 nM. It effectively inhibits growth in various KRAS(G12D)-mutated cancer cell lines, including pancreatic (PK-59, HPAC) and colorectal (GP2d, GP5d) with IC50 values ranging from 3.6 to 29 nM. | Nov 20 2025 |
| E5832 | BBI-2779 | BBI-2779 is a potent, selective, and orally active inhibitor of CHK1 with an IC50 of 0.3 nM. It preferentially kills cancer cells containing extrachromosomal DNA (ecDNA) by inducing replication stress and cell death. In gastric cancer models with FGFR2 gene amplification on ecDNA, BBI-2779 suppresses tumor growth and prevents drug resistance. | Nov 20 2025 |
| E5858 | Chiglitazar (Carfloglitazar) | Chiglitazar (Carfloglitazar) is a potent dual agonist of PPARα and PPARγ with EC50 values of 1.2 μM and 0.08 μM, respectively, and also activates PPARδ with an EC50 of 1.7 μM. It effectively improves insulin resistance and corrects dyslipidemia in monosodium L-glutamate (MSG)-induced obese rats. | Nov 20 2025 |
| E5859 | Acivicin hydrochloride | Acivicin hydrochloride (AT-125 hydrochloride) is the hydrochloride salt of Acivicin, a natural antibiotic produced by Streptomyces sviceus. It is a potent inhibitor of γ-glutamyl transpeptidase (GGT), an enzyme that initiates glutathione catabolism to cysteine. Acivicin also exhibits anti-cancer and anti-parasitic properties. | Nov 20 2025 |
| E5860 | 20-HETE | 20-HETE (20-Hydroxyeicosatetraenoic acid) is a cytochrome P450-derived metabolite of arachidonic acid that plays a dual role in blood pressure regulation. It lowers blood pressure by inhibiting sodium reabsorption and promoting natriuresis in the kidneys, but also raises blood pressure by sensitizing vascular smooth muscle to constrictors, increasing myogenic tone, and inducing endothelial dysfunction. Additionally, 20-HETE stimulates endothelial angiotensin-converting enzyme (ACE), activating a prohypertensive renin-angiotensin-aldosterone system (RAAS) feedback loop that contributes to hypertension and vascular remodeling. | Nov 20 2025 |
| E1983 | BAY-850 | BAY-850 is a potent and isoform-selective inhibitor of the ATPase family AAA domain-containing protein 2 (ATAD2) bromodomain, with an IC50 of 166 nM in TR-FRET assays. It induces ATAD2 bromodomain dimerization and effectively blocks its interaction with acetylated histones in vitro. | Nov 20 2025 |
| E2989 | AZD5904 | AZD5904 is a selective and irreversible human Myeloperoxidase (MPO) inhibitor. AZD5904 reduces 3-chlorotyrosine-modified MYBPC3 levels, restores MYBPC3 phosphorylation, and alleviates the calcium signalling and relaxation defects. | Nov 20 2025 |
| E5915 | Moracin O | Moracin O is a 2-arylbenzofuran isolated from the Morus alba Linn. Moracin O demonstrates potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1) with an IC50 value of 6.76 nM in a cell-based HRE assay. Moracin O attenuates reactive oxygen species (ROS) generation triggered by oxygen-glucose deprivation (OGD). Moracin O also exhibits neuroprotective and anti-inflammatory effects. | Nov 20 2025 |
| E5946 | C12FDG | C12FDG (5-Dodecanoylaminofluorescein di-β-D-galactopyranoside) is a lipophilic green fluorescent probe used to detect β-galactosidase activity. C12FDG demonstrates greater sensitivity for measuring β-galactosidase activity in animal cells than fluorescein di(β-D-galactopyranoside). | Nov 20 2025 |
| E4747 | BMS-986408 | BMS-986408 is a first-in-class dual inhibitor of DGKα and DGKζ, exhibiting IC₅₀ values of 0.0003 μM and 0.002 μM for DGKα and DGKζ lipid kinase activity, respectively. It potentiates T cell–receptor signaling and T-cell activation, enhancing the effectiveness of both PD-1 and CAR T-cell therapy in preclinical models. | Nov 20 2025 |
| E6600 | 3FAx-Neu5Ac | 3FAx-Neu5Ac is a fluorinated sialic acid analogue and an inhibitor of Sialyltransferase. It inhibited sialylation, leading to reduced MHC expression and suppression of myoblast fusion, suggesting that modulation of sialylation can be applied to regulate skeletal muscle cell differentiation. | Nov 20 2025 |
| E6603 | USP5-IN-1 | USP5-IN-1 (compound 64) is a selective competitive inhibitor of USP5 zinc finger ubiquitin binding domain (ZnF-UBD) with a Kd of 2.8 μM. It competitively blocks ubiquitin binding to the ZnF-UBD domain, suppressing USP5 catalytic activity and ubiquitin chain hydrolysis, with potential applications as a chemical probe and therapeutic agent in USP5-related cancers. | Nov 20 2025 |
| E6614 | FABPs ligand 6 (MF6) | FABPs ligand 6 (MF6) is a potent dual inhibitor of FABP5 and FABP7 with KD values of 874 nM and 20 nM, respectively. It rescues mitochondrial function and mitigates FABP5/FABP7-mediated injury, demonstrating potential therapeutic effects in multiple sclerosis (MS). | Nov 20 2025 |
| E6610 | GPX4-IN-5 | GPX4 - IN - 5はGPX4の共有結合性阻害剤です（IC50: 0.12 μM）。GPX4 - IN - 5はフェロプトーシスを誘導し、抗腫瘍効果を有します。GPX4 - IN - 5はトリプルネガティブ乳がん（TNBC）の研究に使用できます。 | Nov 20 2025 |
| E2949 | Talarozole (R115866) | Talarozole (R115866) is a potent, orally active inhibitor of cytochrome P450 (CYP26)-mediated metabolism of All-trans-retinoic acid (RA). It inhibits the conversion of RA by CYP26, with an IC50 of 0.004 µM, and enhances endogenous RA levels and All-trans-retinoic acid receptor (RAR) activation, showing potential as a targeted agent for dermatological therapy. | Nov 20 2025 |
| E1154 | DS18561882 | DS18561882 is a potent, isozyme-selective, and orally available inhibitor of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) with an IC50 value of 0.0063 μM. It exhibits complete tumor growth inhibition in a mouse xenograft model, and shows potential as an anti-cancer agent. | Nov 20 2025 |
| P1253 | Allo-aca (ARV-1803) | Allo-aca (ARV-1803) is a synthetic peptide that functions as a specific antagonist of the leptin receptor, effectively blocking leptin signaling in both in vitro and in vivo. It also demonstrates potential therapeutic applications in the treatment of ophthalmic diseases. | Nov 20 2025 |
| E6608 | HSK31858 | HSK31858 is a reversible inhibitor of DPP-1. It promotes the amelioration of neutrophilic inflammation, demonstrating efficacy and safety in reducing exacerbation frequency in adults with bronchiectasis. | Nov 20 2025 |
| E1963 | ARV-393 | ARV-393 is a highly potent, orally bioavailable BCL6 PROTAC degrader. ARV-393 promotes rapid BCL6 degradation through the cells ubiquitin-proteasome pathway. ARV-393 demonstrates DC50 and GI50 values <1 nM in numerous DLBCL and BL cell lines. | Nov 19 2025 |
| F1318 | XPA Antibody [H4H1] | Nov 12 2025 | |
| F5072 | Cox1 Antibody [N11K4] | Nov 12 2025 | |
| F2797 | TP53INP1 Antibody [N17J20] | Nov 12 2025 | |
| F1102 | OTUB1 Antibody [F10D20] | Nov 12 2025 | |
| F2335 | Phospho-PKCθ/PRKCQ (Thr538) Antibody [D2M12] | Phospho-PKCθ (Thr538),PKC theta/PRKCQ (phospho T538) | Nov 12 2025 |
| F1062 | E2F-1 Antibody [N6L18] | E2F 1,E2F1,E2F-1 | Nov 12 2025 |
| F3041 | Connexin 43 Antibody [F6F11] | Connexin 43,Connexin 43 / GJA1,Connexin-43 | Nov 12 2025 |
| F3052 | Phospho-SLP-76 (Ser376) Antibody [K18E5] | Nov 12 2025 | |
| F0356 | RUNX2 Antibody [L18D16] | Nov 12 2025 | |
| F0405 | Phospho-c-Fos (Ser32) Antibody [H14J15] | Nov 12 2025 | |
| F4205 | cGAS Antibody [L20A17] | Nov 12 2025 | |
| F4213 | HMGB1 Antibody [N2J9] | Nov 12 2025 | |
| F4216 | CaMKII (pan) Antibody [G5E11] | Nov 12 2025 | |
| F4332 | CaMKIIβ Antibody [C10N23] | Nov 12 2025 | |
| F4673 | Topoisomerase IIα Antibody [H22C21] | Nov 12 2025 | |
| F4675 | PFKFB3 Antibody [A21K14] | Nov 12 2025 | |
| F4554 | Palladin Antibody [M23E22] | Nov 12 2025 | |
| F2625 | c-Jun Antibody [M24E3] | Nov 12 2025 | |
| F2850 | JAK2 Antibody [J11G12] | Nov 12 2025 | |
| F0858 | RagB Antibody [F4J9] | Nov 12 2025 | |
| F3042 | PKD/PKCμ Antibody [D22N3] | PKC mu/PKD,PKD/PKCμ,PRKD1 | Nov 12 2025 |
| F3928 | Claudin 2 Antibody [K9A14] | Nov 12 2025 | |
| F4102 | PVR/CD155 Antibody [D7N14] | Nov 12 2025 | |
| F4107 | Phospho-p38 MAPK (Tyr182) Antibody [H7F4] | Nov 12 2025 | |
| F4416 | PGC1α/β Antibody [H5N22] | Nov 12 2025 | |
| F4661 | Keratin 20 Antibody [L17C14] | Nov 12 2025 | |
| F4662 | AML1 Antibody [M14L22] | Nov 12 2025 | |
| F4337 | Claudin 7 Antibody [M7D16] | Nov 12 2025 | |
| F4698 | Acetyl-Histone H4 (Lys5) Antibody [N10C10] | Nov 12 2025 | |
| F4704 | UCHL1 Antibody [A3D22] | Nov 12 2025 | |
| F4731 | TRXR1 Antibody [M16L20] | Nov 12 2025 | |
| F4706 | MEK1 Antibody [G24C19] | Nov 12 2025 | |
| F1554 | KPNB1 Antibody [K10N6] | Importin beta-1,Importin β1,karyopherin β1,KPNB1 | Nov 12 2025 |
| F4732 | RBX1 Antibody [F19G22] | Nov 12 2025 | |
| F4776 | ASH2L Antibody [G9J14] | Nov 12 2025 | |
| F4778 | Aquaporin 5 Antibody [N22D4] | Nov 12 2025 | |
| F1335 | GOPC Antibody [F21D16] | GOPC,PIST | Nov 12 2025 |
| F4775 | TRIM21/SS-A Antibody [A14D15] | Nov 12 2025 | |
| F4780 | CSK Antibody [M12C3] | Nov 12 2025 | |
| F2934 | Antithrombin III/ATIII Antibody [F5E18] | Nov 12 2025 | |
| F5073 | LAG3 Antibody [B14L17] | Nov 12 2025 | |
| F5080 | DLAT Antibody [N14J24] | Nov 12 2025 | |
| F2752 | CSNK1A1 + CSNK1A1L Antibody [M11N18] | Nov 12 2025 | |
| F2880 | Calnexin (ER Membrane Marker) Antibody [H16B4] | Calnexin,Calnexin - ER membrane marker | Nov 12 2025 |
| F2895 | SMURF1 Antibody [H21P21] | Nov 12 2025 | |
| F2929 | SUN1 Antibody [C6L1] | Nov 12 2025 | |
| F3383 | NOTCH3 Antibody [G6A6] | Nov 12 2025 | |
| F3395 | SCD1 Antibody [H13N22] | SCD1 | Nov 12 2025 |
| F3362 | KDM1/LSD1 (Nuclear Marker) Antibody [P12K1] | KDM1/LSD1,LSD1 | Nov 12 2025 |
| F3454 | SorLA/SORL1 Antibody [G6C20] | SORL1,SorLA/SORL1 | Nov 12 2025 |
| F3593 | Drosha Antibody [H19L17] | Nov 12 2025 | |
| F2549 | CRMP1 + CRMP2 Antibody [P10G14] | Nov 12 2025 | |
| F5014 | AFP Antibody [C4N14] | Nov 12 2025 | |
| F4588 | HPK1 Antibody [G24G15] | Nov 12 2025 | |
| F5036 | PFKFB2 Antibody [P13H13] | Nov 12 2025 | |
| F0132 | CHOP Antibody [K6F19] | CHOP,DDIT3,DDIT3/GADD153/CHOP,GADD153/CHOP | Nov 12 2025 |
| F0785 | JMJD2A Antibody [B12L5] | JMJD2A,KDM4A / JHDM3A / JMJD2A | Nov 12 2025 |
| F1458 | ISG15 Antibody [H10C1] | Nov 12 2025 | |
| F3666 | ERAB Antibody [M20E24] | Nov 12 2025 | |
| F2804 | IGF2BP2/IMP-2 Antibody [H6A9] | IGF2BP2/IMP-2,IMP2,IMP-2 | Nov 12 2025 |
| F3665 | Phospho-NEDD4-2 (Ser448) Antibody [D21H23] | NEDD4-2 (phospho S448),Phospho-NEDD4L (Ser448) | Nov 12 2025 |
| F4643 | CHIP Antibody [C8P21] | Nov 12 2025 | |
| F4741 | PSMD14 Antibody [G24K15] | Nov 12 2025 | |
| F4784 | Thymidine Phosphorylase Antibody [E2G2] | Nov 12 2025 | |
| F5028 | 4F2hc/CD98 Antibody [J3D15] | Nov 12 2025 | |
| F4745 | LAMTOR4/C7orf59 Antibody [B13E17] | Nov 12 2025 | |
| F4753 | Ikaros Antibody [L1F4] | Nov 12 2025 | |
| F4790 | CYP11A1 Antibody [N14H6] | Nov 12 2025 | |
| F4966 | CNOT1 Antibody [G16N7] | Nov 12 2025 | |
| F4995 | METTL3 Antibody [F21G6] | Nov 12 2025 | |
| F5076 | PAX5 Antibody [A13D19] | Nov 12 2025 | |
| F0352 | Phospho-YAP (Ser127) Antibody [K8E8] | Phospho-YAP (Ser127),YAP1 (phospho S127) | Nov 12 2025 |
| F1400 | CCR2 Antibody [F5J21] | Nov 12 2025 | |
| F3630 | NDUFB11 Antibody [B16A12] | Nov 12 2025 | |
| F3841 | Leukotriene A4 hydrolase/LTA4H Antibody [K11F14] | Nov 12 2025 | |
| F3776 | Citrate synthetase Antibody [K19C21] | Citrate Synthase,Citrate synthetase | Nov 12 2025 |
| F4548 | LEPRE1 Antibody [A19A13] | Nov 12 2025 | |
| F3865 | DLC-A Antibody [E10K8] | Nov 12 2025 | |
| F4166 | Nectin-2/CD112 Antibody [A4N1] | Nov 12 2025 | |
| F4131 | c-Fos Antibody [B8E19] | Nov 12 2025 | |
| F4147 | HER2/ErbB2 Antibody [G18G3] | Nov 12 2025 | |
| F4151 | EEA1 Antibody [G20J24] | Nov 12 2025 | |
| F4366 | G Protein Goα Antibody [K6C9] | Nov 12 2025 | |
| F4760 | mGluR1 Antibody [H16E18] | Nov 12 2025 | |
| F4967 | LONP1 Antibody [L16G15] | Nov 12 2025 | |
| F4992 | RHAMM/CD168 Antibody [F19D7] | Nov 12 2025 | |
| F5037 | TMEM49/VMP1 Antibody [M12G17] | Nov 12 2025 | |
| F5083 | S5a/PSMD4 Antibody [K9M17] | Nov 12 2025 | |
| F4991 | NEK7 Antibody [M18K14] | Nov 12 2025 | |
| F0641 | NUT Antibody [M11K3] | Nov 12 2025 | |
| F2876 | Phospho-FAK (Tyr397) Antibody [G24K11] | FAK (phospho Y397),FAK (Tyr397),p-FAK,Phospho-FAK (Tyr397) | Nov 12 2025 |
| F3197 | IL-12A Antibody [M13B8] | Nov 12 2025 | |
| F2692 | ATP1A3 Antibody [M10F4] | ATP1A3,Sodium Potassium ATPase Alpha 3 | Nov 12 2025 |
| F2178 | CXCR4 Antibody [G11H20] | CXCR4,CXCR-4 | Nov 12 2025 |
| F3694 | Phospho-Glucose Transporter GLUT4 (Ser488) Antibody [A20E7] | Nov 12 2025 | |
| F2103 | PADI4/PAD4 Antibody [B6N23] | Nov 12 2025 | |
| F1518 | CD56 Antibody [C5A9] | CD56,CD56 (NCAM),Neural Cell Adhesion Molecule | Nov 12 2025 |
| F4730 | c-Myb Antibody [P19K4] | Nov 12 2025 | |
| F2096 | EGFP Antibody [G6F5] | Nov 12 2025 | |
| E6559 | GS-1427 | GS-1427 (Emvistegrast) is an oral, small-molecule quinolone derivative that functions as a potent and selective antagonist of α4β7 integrin, with the potential treatment of inflammatory bowel disease. | Nov 12 2025 |
| F3330 | Phospho-LRRK2 (Ser955) Antibody [F1M24] | Nov 10 2025 | |
| F2920 | Endothelium Antibody [M4F6] | Nov 10 2025 | |
| F3553 | Phospho-SMAD2 (Ser245/250/255) Antibody [H4M3] | Nov 10 2025 | |
| F3893 | Phospho-PERK (Thr982) Antibody [A3P5] | Nov 10 2025 | |
| F3027 | CD54/ICAM-1 Antibody [G22B20] | CD54/ICAM-1,ICAM1,ICAM-1,ICAM-1/CD54 | Nov 10 2025 |
| F3648 | C9 Antibody [F9K1] | Nov 10 2025 | |
| F3706 | Cathelicidin/CLP Antibody [G7D10] | Cathelicidin/CLP,LL-37 | Nov 10 2025 |
| F3962 | Epac1 Antibody [N21J24] | Nov 10 2025 | |
| F3917 | CASPR/Neurexin IV Antibody [G14B9] | Nov 10 2025 | |
| F4015 | NCAM1 Antibody [G16N2] | Nov 10 2025 | |
| F4028 | PD-L2 Antibody [C11K4] | Nov 10 2025 | |
| F4042 | Phospho-STAT6 (Tyr641) Antibody [G7E12] | Nov 10 2025 | |
| F4139 | Phospho-VEGF Receptor 2 (Tyr1175) Antibody [M10N15] | Nov 10 2025 | |
| F4141 | NRF2 Antibody [J1K11] | Nov 10 2025 | |
| F0817 | TIMP3 Antibody [C11F19] | TIMP3,TIMP-3 | Nov 10 2025 |
| F0944 | DcR2 Antibody [J5A17] | DcR2,TRAILR4/TNFRSF10D/DcR2 | Nov 10 2025 |
| F4100 | GW182 Antibody [B20J19] | Nov 10 2025 | |
| F4156 | iNOS Antibody [M12M8] | Nov 10 2025 | |
| F4159 | JARID1B Antibody [A10D8] | Nov 10 2025 | |
| F3988 | SOX6 Antibody [F11P10] | Nov 10 2025 | |
| F4089 | Phospho-EGF Receptor (Tyr1173) Antibody [E8J4] | Nov 10 2025 | |
| F3944 | Desmocollin 2/3 Antibody [P8E9] | Nov 10 2025 | |
| F4327 | ESPL1 Antibody [B22J16] | Nov 10 2025 | |
| F0595 | Phospho-EphA2 (Ser897) Antibody [G4G3] | Nov 10 2025 | |
| F4198 | Glut1 Antibody [C8B12] | Nov 10 2025 | |
| F4183 | K48-linkage Specific Polyubiquitin Antibody [B3A13] | Nov 10 2025 | |
| F4186 | XBP-1s Antibody [N17H18] | Nov 10 2025 | |
| F4188 | PGC-1α Antibody [J17F10] | Nov 10 2025 | |
| F3779 | Histone H2A Antibody [L10L6] | Histone H2A,Histone H2A II | Nov 10 2025 |
| F4157 | TR4/NR2C2 Antibody [C17H11] | Nov 10 2025 | |
| F4191 | Puma Antibody [L5K18] | Nov 10 2025 | |
| F4190 | LRP6 Antibody [D22K11] | Nov 10 2025 | |
| F4223 | Shh Antibody [L19M13] | Nov 10 2025 | |
| F4214 | DNMT3A Antibody [E19E6] | Nov 10 2025 | |
| F4235 | MNX1/HB9 Antibody [M23L14] | Nov 10 2025 | |
| F4986 | DLL4 Antibody [G18K6] | Nov 10 2025 | |
| F4645 | CD4 Antibody [D18N16] | Nov 10 2025 | |
| F4649 | IRF-8 Antibody [B11H19] | Nov 10 2025 | |
| F5075 | SOS1 Antibody [N10K2] | Nov 10 2025 | |
| F2853 | PD-L1 Antibody [G4H2] | CD274 (PD-L1, B7-H1),PD-L1 | Nov 10 2025 |
| F4195 | Notch2 Antibody [J1H19] | Nov 10 2025 | |
| F4600 | Catalase Antibody [A24M22] | Nov 10 2025 | |
| F4613 | Phospho-PKA C (Thr197) Antibody [L13C4] | Nov 10 2025 | |
| F4646 | ROCK2 Antibody [G16E9] | Nov 10 2025 | |
| F4700 | BCL6 Antibody [B14D22] | Nov 10 2025 | |
| F1510 | ASF1B Antibody [N9K17] | Nov 10 2025 | |
| F4711 | RXRα Antibody [M1G17] | Nov 10 2025 | |
| F5074 | NKX3.1 Antibody [C3L21] | Nov 10 2025 | |
| F3392 | ARID1A Antibody [E15D7] | ARID1A,ARID1A/BAF250A | Nov 10 2025 |
| F2720 | KDEL Antibody [E23K12] | Nov 10 2025 | |
| F1945 | VRK1 Antibody [L11L3] | Nov 10 2025 | |
| F4589 | USP13 Antibody [H16J11] | Nov 10 2025 | |
| F4656 | Merlin Antibody [D2J18] | Nov 10 2025 | |
| F4355 | Centrin Antibody [H9B14] | Nov 10 2025 | |
| F4659 | IKKγ Antibody [D1B9] | Nov 10 2025 | |
| F4651 | Lamin B2 Antibody [C21M24] | Nov 10 2025 | |
| F5007 | DDX5 Antibody [G17N23] | Nov 10 2025 | |
| F4998 | Atg4A Antibody [P12G1] | Nov 10 2025 | |
| F5018 | α-E-Catenin Antibody [D17G1] | Nov 10 2025 | |
| F0348 | Phospho-Smad1/5 (Ser463/465) Antibody [H6D11] | Nov 10 2025 | |
| F1010 | PSMA Antibody [N17H9] | Prostate Specific Membrane Antigen,PSMA,PSMA (FOLH1) | Nov 10 2025 |
| F4658 | p38α MAPK Antibody [N19P8] | Nov 10 2025 | |
| F4989 | Trk (pan) Antibody [N18M6] | Nov 10 2025 | |
| F3998 | AKR1C3 Antibody [M22N11] | Nov 10 2025 | |
| E6539 | SHOC2–RAS PPI-IN-1 | SHOC2-RAS PPI-IN-1（化合物6）は、SHOC2とRASタンパク質の相互作用を標的とする非共有結合性の競合的阻害剤です。SHOC2-RAS PPI-IN-1は、NRASQ61Rに対するIC50が0.048μM、KDが0.065μMです。SHOC2-RAS PPI-IN-1は、SMPホスファターゼ複合体の活性を阻害し、CRAFS259のリン酸化レベルを上昇させることで、MAPKシグナル伝達経路を遮断し（例えば、pMEKとpERKのレベルを低下させ）、腫瘍細胞周期の停止とアポトーシスを誘導します。SHOC2-RAS PPI-IN-1は、NRASQ61R変異を持つ黒色腫や結腸直腸癌などの悪性腫瘍の標的研究に使用できます。 | Nov 10 2025 |
| F2627 | Synaptotagmin1 Antibody [K23K15] | Synaptotagmin I,Synaptotagmin-1 | Nov 10 2025 |
| F0823 | TLR3 Antibody [P15K10] | CD283 (TLR3),TLR3,Toll-like Receptor 3 | Nov 10 2025 |
| F1277 | CISH Antibody [J15C14] | Nov 10 2025 | |
| F3685 | Human IgA Antibody [D12J14] | Nov 10 2025 | |
| F1300 | Phospho-SGK1 (Ser78) Antibody [E23F7] | Nov 10 2025 | |
| F1462 | Phospho-FLT3 (Tyr589/591) Antibody [K5L11] | Nov 10 2025 | |
| F1549 | Phospho-LRRK2 (Ser935) Antibody [K11C19] | Nov 10 2025 | |
| F1323 | BATF Antibody [G1B2] | Nov 10 2025 | |
| F0852 | Phospho-EphA2 (Tyr588) Antibody [F13K2] | Nov 10 2025 | |
| F1649 | Phospho-SRC Family (Tyr418) Antibody [H7L14] | Nov 10 2025 | |
| F3425 | Factor H Antibody [H24L2] | Nov 10 2025 | |
| F0256 | Phospho-VEGF Receptor 2 (Tyr1175) Antibody [M9C2] | Phospho-VEGF Receptor 2 (Tyr1175),VEGF Receptor 2 (phospho Y1175) | Nov 10 2025 |
| F0291 | Notch1 Antibody [L20J9] | activated Notch1,Notch1 | Nov 10 2025 |
| F2979 | LRG1/LRG Antibody [K9H24] | Nov 10 2025 | |
| F2175 | Phospho-DNA PKcs (Ser2056) Antibody [M17B5] | DNA PKcs (phospho S2056),Phospho-DNA-PKcs (Ser2056) | Nov 10 2025 |
| F3166 | NMNAT2 Antibody [H1N2] | Nov 10 2025 | |
| F2641 | PTCH1 Antibody [K3H23] | Patched / PTCH1,PTCH1 | Nov 10 2025 |
| F2213 | IL-2 Antibody [K8L21] | Nov 10 2025 | |
| F3427 | Serum Amyloid A Antibody [E21J5] | Nov 10 2025 | |
| F2376 | PON1 Antibody [G1G1] | Nov 10 2025 | |
| F2670 | PD-L1 Antibody [P4L19] | CD274 (PD-L1, B7-H1),PD-L1 | Nov 10 2025 |
| F2668 | 4-1BB/CD137/TNFRSF9 Antibody [E8D4] | Nov 10 2025 | |
| F2131 | Smoothelin Antibody [L15K16] | Nov 10 2025 | |
| F2378 | S100A9 Antibody [N6K8] | Nov 10 2025 | |
| F2406 | Elastin Antibody [E23J23] | Nov 10 2025 | |
| F2123 | Psoriasin Antibody [L12L3] | Psoriasin,S100A7,S100A7/Psoriasin | Nov 10 2025 |
| F2197 | DnaK Antibody [E21A24] | Nov 10 2025 | |
| F2391 | Mast Cell Chymase (C-terminal) Antibody [G3B5] | Chymase,Mast Cell Chymase | Nov 10 2025 |
| F1920 | Tryptophan/Tyrosine/Phenylalanine Hydroxylase Antibody [A9C1] | Nov 10 2025 | |
| F2448 | BRN3A Antibody [H20L3] | BRN3A,Brn-3a,Brn-3a/BRN3A/POU4F1 | Nov 10 2025 |
| F2918 | SET7 Antibody [G9K21] | SET7,SET7/SET9 | Nov 10 2025 |
| F2955 | MIF Antibody [M24J2] | Nov 10 2025 | |
| F3119 | MASH1 Antibody [L14N8] | ASCL1,MASH1,MASH1/Achaete-scute homolog 1 | Nov 10 2025 |
| F2972 | groEL Antibody [K3P10] | Nov 10 2025 | |
| E6589 | 2BAct | 2BActは、EC50が33 nMの、高度に選択的で経口活性のあるeIF2B（真核生物開始因子2B）活性化剤です。2BActは、慢性的な統合ストレス応答によって引き起こされる神経学的欠陥を防ぎます。2BActは中枢神経系（CNS）に浸透することができます。2BActは、eIF2B活性化剤ISRIBトランス異性体（HY - 12495）と比較して、溶解性と薬物動態が改善されています。 | Nov 09 2025 |
| E5972 | ZINC00784494 | ZINC00784494は、特定のリポカリン - 2（LCN2）阻害剤です。ZINC00784494は、SUM149細胞において細胞増殖と細胞生存能力を阻害し、AKTリン酸化レベルを低下させます。ZINC00784494は、炎症性乳がん（IBC）の研究において良好な可能性を持っています。 | Nov 03 2025 |
| E6536 | Antalarmin hydrochloride | アンタラルミン（塩酸塩）は、Kiが1 nMの経口活性型非ペプチドコルチコトロピン放出ホルモン受容体1（CRHR1）拮抗薬です。塩酸アンタラルミンは、CRH誘発性のACTH分泌を抑制し、動物モデルにおいてCRHおよび新規刺激誘発性の不安様行動を阻害します。塩酸アンタラルミンは、関節炎モデルにおいて抗炎症効果を示し、過敏性腸症候群に関連するストレス誘発性の胃潰瘍を抑制します。 | Nov 03 2025 |
| E6534 | Safusidenib | サフシデニブ（AB - 291；DS - 1001）は、経口投与可能な選択的変異型IDH1阻害剤です。サフシデニブは変異型IDH1を強力に阻害しますが、野生型IDH1は阻害しません。サフシデニブは軟骨肉腫における腫瘍活性を阻害します。サフシデニブは、事前インキュベーションを行わないアッセイにおいて、IDH1R132HおよびIDH1R132Cに対してそれぞれ15 nMおよび130 nMのIC50で活性を示します。 | Nov 03 2025 |
| E6576 | Valiltramiprosate | ALZ - 801は、強力で経口投与可能な小分子のβ-アミロイド（Aβ）抗オリゴマーおよび凝集阻害剤であり、トラミプロサートのバリン結合型前駆薬であり、親化合物と比較して薬物動態特性と消化管耐受性が大幅に改善されています。ALZ - 801は、アルツハイマー病の治療における高度で著しく改善された候補薬です。 | Nov 03 2025 |
| E5971 | ZINC00640089 | ZINC00640089は、特定のリポカリン-2（LCN2）阻害剤です。ZINC00640089は、SUM149細胞において細胞増殖と細胞生存を阻害し、AKTリン酸化レベルを低下させます。ZINC00640089は、炎症性乳がん（IBC）の研究において良好な可能性を持っています。 | Oct 28 2025 |
| E6541 | PolQi2 | PolQi2は、PolΘのN末端のヘリカーゼドメインを阻害することで、alt - EJ（代替末端結合）修復を標的として阻害するPolΘ阻害剤です。PolQi2は、異なる遺伝子座および様々な細胞株における遺伝子編集の精度と組み込み効率を向上させます。さらに、PolQi2とDNA - PK阻害剤を併用すると、Cas9のオフターゲット効果が低減されます。PolQi2は遺伝子編集研究に使用できます。 | Oct 28 2025 |
| E6522 | HRS-9821 | PDE3/4 - IN - 2（化合物1）はPDE3/PDE4の二重標的阻害剤で、PDE3AおよびPDE4B1に対するIC50値はそれぞれ0.13 nMおよび50 nMです。PDE3/4 - IN - 2は、喘息、閉塞性肺疾患、敗血症、腎炎などのPDE関連疾患の研究に使用できます。 | Oct 22 2025 |
| E1076 | Linperlisib | リンペルリシブは、特許WO 2015055071 A1の化合物10から抽出された強力で経口投与可能な選択的PI3Kδ阻害剤であり、IC50は6.4 nMである。 | Oct 15 2025 |
| E6577 | 1-Naphthohydroxamic acid | 1-ナフトヒドロキサム酸（化合物2）は、IC50が14 μMの強力かつ選択的なHDAC8阻害剤です。1-ナフトヒドロキサム酸は、クラスIのHDAC1およびクラスIIのHDAC6（IC50 >100 μM）よりもHDAC8に対して選択性が高いです。1-ナフトヒドロキサム酸は、グローバルなヒストンH4のアセチル化を増加させず、また細胞内の総HDAC活性を低下させません。1-ナフトヒドロキサム酸はチューブリンのアセチル化を誘導することができます。 | Oct 15 2025 |
| F4103 | SIRPα/SHPS1 Antibody [E18F24] | Oct 13 2025 | |
| F3634 | Elav-type RNA-binding protein ETR3 Antibody [M8J19] | CUGBP2,CUG-BP2,Elav-type RNA-binding protein ETR3 | Oct 13 2025 |
| F0344 | Phospho-LATS1 (Thr1079) Antibody [F2E16] | Oct 13 2025 | |
| F0381 | GLI1 Antibody [A19H14] | GLI1,GLI-1,GLI-1/GLI1 | Oct 13 2025 |
| F0126 | Ki67 Antibody [J16J15] | Ki67,Ki-67,Ki67/MKI67,Mki67,Proliferating Cell Protein Ki-67 | Oct 13 2025 |
| F0546 | LATS2 Antibody [E7E9] | Oct 13 2025 | |
| F0501 | Phospho-Rb (Ser780) Antibody [L13P18] | Phospho-Rb (Ser780),Progesterone Receptor,Rb (phospho S780) | Oct 13 2025 |
| F0871 | eNOS/NOS Type III Antibody [L17A10] | eNOS,eNOS/NOS Type III,NOS3 | Oct 13 2025 |
| F0486 | NMDA Receptor 1 (GluN1) Antibody [D10D12] | NMDA Receptor 1 (GluN1),NMDAR1,NR1 | Oct 13 2025 |
| F1266 | TET2 Antibody [P14B7] | Oct 13 2025 | |
| F1319 | ZO-3 Antibody [A9A20] | ZO-3,Zonula occludens protein 3/ZO3 | Oct 13 2025 |
| F1589 | Tenascin C Antibody [D15E11] | Oct 13 2025 | |
| F2045 | Firefly Luciferase Antibody [H5E21] | Firefly Luciferase,Luciferase | Oct 13 2025 |
| F1490 | RhoE Antibody [A21D22] | Oct 13 2025 | |
| F2144 | Granzyme B Antibody [B18E4] | Oct 13 2025 | |
| F0752 | Phospho-PLCγ1 (Tyr783) Antibody [C6N17] | Phospholipase C gamma 1/PLC-gamma-1 (phospho Y783),Phospho-PLCγ1 (Tyr783) | Oct 13 2025 |
| F1511 | P2X7 Receptor Antibody [L17L11] | P2X7,P2X7 Receptor | Oct 13 2025 |
| F2232 | Acetyl-p53 (Lys382) Antibody [K2J24] | Acetyl-p53 (Lys382),p53 (acetyl K382) | Oct 13 2025 |
| F2644 | Phospho-JAK1 (Tyr1034/1035)/JAK2 (Tyr1007/1008) Antibody [L3G19] | Oct 13 2025 | |
| F2205 | Nephrin Antibody [L16L12] | Oct 13 2025 | |
| F2211 | LAG3 Antibody [K23N22] | CD223,CD223 (LAG-3),LAG3 | Oct 13 2025 |
| F2333 | Phospho-p70 S6K (Thr421/Ser424) Antibody [E5J12] | p70 S6K phospho Thr421 Ser424,Phospho-p70 S6 Kinase (Thr421/Ser424) | Oct 13 2025 |
| F2518 | Oct4 Antibody [K18A18] | Oct3/4,Oct-3/4,Oct4,Oct-4,OCT-4 [POU5F1] | Oct 13 2025 |
| F2523 | Cleaved Caspase-3 Antibody [G2J3] | Caspase 3,Caspase-3 | Oct 13 2025 |
| F2209 | S100 Antibody [H19D4] | S100,S-100,S100 alpha,S-100 Protein | Oct 13 2025 |
| F2819 | Ras (mutated Q61R) Antibody [E15B9] | Oct 13 2025 | |
| F0232 | LATS1 Antibody [A5C10] | LATS1,LATS1/WARTS | Oct 13 2025 |
| F2747 | Phospho-FGFR3 (Tyr724) Antibody [K24F17] | Oct 13 2025 | |
| F2966 | CARD15/NOD2 Antibody [J24G22] | CARD15/NOD2,NOD2 | Oct 13 2025 |
| F2690 | V5 Tag Antibody [L19E11] | Paramyxovirus SV5 Pk,V5,V5 Epitope Tag,V5 Tag,V5-Probe,V5-Tag | Oct 13 2025 |
| F2986 | Activin Receptor Type IIB/ACVR2B Antibody [A7P16] | Oct 13 2025 | |
| F3178 | Hsp20 N-terminal Antibody [B22P24] | Oct 13 2025 | |
| F2680 | Myelin Oligodendrocyte Glycoprotein Antibody [J5E10] | MOG,Myelin oligodendrocyte glycoprotein,Myelin Oligodendrocyte Glycoprotein (MOG) | Oct 13 2025 |
| F2570 | TPP1 Antibody [G7K15] | Oct 13 2025 | |
| F3351 | IL-34 Antibody [D20H18] | Oct 13 2025 | |
| F3416 | PHF1 Antibody [M20F24] | Oct 13 2025 | |
| F3138 | ATP7b Antibody [K8A2] | Oct 13 2025 | |
| F3169 | IL36 γ/IL-1F9 Antibody [J11G22] | Oct 13 2025 | |
| F3133 | ARF1 Antibody [P21G11] | Oct 13 2025 | |
| F3609 | Phospho-Rb (Thr373) Antibody [F9H20] | Oct 13 2025 | |
| F3247 | PINK1 Antibody [M4A21] | Oct 13 2025 | |
| F3248 | c-Kit Antibody [C9J3] | CD117(c-kit),c-Kit | Oct 13 2025 |
| F3837 | Phospho-Insulin Receptor (Tyr1185) Antibody [D6L11] | Oct 13 2025 | |
| F3854 | Periostin Antibody [C16F13] | Oct 13 2025 | |
| F3975 | Metabotropic Glutamate Receptor 2 + 3 Antibody [K11L17] | Oct 13 2025 | |
| F4011 | CD4 Antibody [F12H10] | Oct 13 2025 | |
| F4072 | Phospho-c-Jun (Ser63) Antibody [E24K1] | Oct 13 2025 | |
| F3875 | Lyn Antibody [F9H10] | Oct 13 2025 | |
| F4044 | Phospho-RSK1 p90 (Thr359) Antibody [L24F14] | Oct 13 2025 | |
| F4076 | PDGFR α Antibody [E14D18] | Oct 13 2025 | |
| F4078 | GATA-3 Antibody [M8D4] | Oct 13 2025 | |
| F4110 | LOXL2 Antibody [P18K4] | Oct 13 2025 | |
| F4148 | Cleaved Caspase-9 (Asp330) Antibody [M4F20] | Oct 13 2025 | |
| F3826 | transgelin/SM22 Antibody [H9M7] | Oct 13 2025 | |
| F3986 | Dishevelled 3 Antibody [J9L3] | Oct 13 2025 | |
| F4071 | APPL Antibody [P12M22] | Oct 13 2025 | |
| F4084 | β-Catenin Antibody [E8L3] | Oct 13 2025 | |
| F4087 | Phospho-Akt1 (Ser473) Antibody [K10L8] | Oct 13 2025 | |
| F4091 | Aurora B/AIM1 Antibody [M7F7] | Oct 13 2025 | |
| F4115 | ASS1 Antibody [B13C24] | Oct 13 2025 | |
| F4117 | GATA-2 Antibody [N19H2] | Oct 13 2025 | |
| F4119 | CDK2 Antibody [B5A8] | Oct 13 2025 | |
| F4133 | COX IV Antibody [A4F21] | Oct 13 2025 | |
| F4158 | Phospho-Histone H3 (Thr3) Antibody [C4K12] | Oct 13 2025 | |
| F4161 | LRF/Pokemon Antibody [E18A16] | Oct 13 2025 | |
| F4164 | FEN-1 Antibody [P22D7] | Oct 13 2025 | |
| F4165 | Ron Antibody [E10H2] | Oct 13 2025 | |
| F4170 | VE-Cadherin Antibody [K17A2] | Oct 13 2025 | |
| F4177 | EGR1 Antibody [A20H11] | Oct 13 2025 | |
| F4179 | LKB1 Antibody [M21A16] | Oct 13 2025 | |
| F4180 | Mitofusin-2 Antibody [C8L13] | Oct 13 2025 | |
| F4181 | MMP-2 Antibody [C12L21] | Oct 13 2025 | |
| F4182 | Phospho-4E-BP1 (Ser65) Antibody [K24A12] | Oct 13 2025 | |
| F4184 | c-IAP2 Antibody [J16G5] | Oct 13 2025 | |
| F4187 | Histone H3 (di methyl Lys4) Antibody [P13F3] | Oct 13 2025 | |
| F4201 | TRAF6 Antibody [B8B10] | Oct 13 2025 | |
| F4212 | NF-κB1 p105/p50 Antibody [J15F15] | Oct 13 2025 | |
| F4217 | SDHA Antibody [D7C19] | Oct 13 2025 | |
| F4220 | Zap-70 Antibody [E5E23] | Oct 13 2025 | |
| F4231 | IGFBP1 Antibody [P3H15] | Oct 13 2025 | |
| F4234 | Phospho-CrkL (Tyr207) Antibody [B13N10] | Oct 13 2025 | |
| F4237 | Arginase-2 Antibody [L5B23] | Oct 13 2025 | |
| F4240 | Phospho-CDC37 (Ser13) Antibody [G22K18] | Oct 13 2025 | |
| F4250 | Neurofilament-H Antibody [P21P23] | Oct 13 2025 | |
| F4363 | EF1α Antibody [M10N21] | Oct 13 2025 | |
| F4407 | GRK 4/5/6 Antibody [P12B19] | Oct 13 2025 | |
| F4608 | PKR Antibody [F1M21] | Oct 13 2025 | |
| F4660 | PSA/KLK3 Antibody [M14P16] | Oct 13 2025 | |
| F4750 | GFAT1 Antibody [D8D23] | Oct 13 2025 | |
| F4887 | Hsp90 α Antibody [E20C4] | Oct 13 2025 | |
| F4988 | Prostate Specific Membrane Antigen Antibody [A11C13] | Oct 13 2025 | |
| F4990 | NDRG4 Antibody [K2B13] | Oct 13 2025 | |
| F3987 | PRKACG Antibody [H19A15] | Oct 13 2025 | |
| F3989 | eIF4A1 Antibody [C7L14] | Oct 13 2025 | |
| F3993 | ANK-3 Antibody [M12B24] | Oct 13 2025 | |
| F3994 | LAMP2A Lysosome Marker Antibody [M18B14] | Oct 13 2025 | |
| F3996 | HP1 γ/CBX3 Antibody [N9P19] | Oct 13 2025 | |
| F4010 | MiTF Antibody [B21F15] | Oct 13 2025 | |
| F4070 | HAUSP/USP7 Antibody [B16C12] | Oct 13 2025 | |
| F4196 | PI3 Kinase p110β Antibody [D23E3] | Oct 13 2025 | |
| F4209 | RelB Antibody [A5J20] | Oct 13 2025 | |
| F4221 | STAT5 Antibody [B9G7] | Oct 13 2025 | |
| F4242 | RAP80 Antibody [P19F10] | Oct 13 2025 | |
| F4244 | Sec24D Antibody [P23J18] | Oct 13 2025 | |
| F4248 | Histone H3 (mono Methyl Lys9) Antibody [E5H2] | Linperlisib (YY-20394) is a highly selective, orally bioavailable PI3Kδ inhibitor with an IC50 value of 6.4 nM, as disclosed in patent WO 2015055071 A1 (compound 10). | Oct 13 2025 |
| F4339 | Cytokeratin Pan Type I Antibody [G3A2] | 1-Naphthohydroxamic acid (Compound 2) demonstrates potent and selective inhibition of HDAC8 (IC50 = 14 μM), exhibiting significantly greater selectivity for HDAC8 compared to class I HDAC1 and class II HDAC6 (IC50 >100 μM). This compound does not elevate global histone H4 acetylation levels nor decrease total intracellular HDAC activity. Additionally, 1-naphthohydroxamic acid has been shown to promote tubulin acetylation. | Oct 13 2025 |
| F4386 | Histone Antibody [E15A19] | Oct 13 2025 | |
| F4396 | GRK 2/3 (βARK 1/2) Antibody [K24G8] | Oct 13 2025 | |
| F3245 | IRF1 Antibody [H12G6] | Oct 13 2025 | |
| F2422 | PRMT1 Antibody [B18H13] | PRMT1 | Oct 13 2025 |
| F3887 | PIM2 Antibody [L18N23] | Oct 13 2025 | |
| F2520 | RhoA Antibody [B21G13] | Rho A,RhoA | Oct 13 2025 |
| F3597 | PFKM + PFKP Antibody [B11E20] | Oct 13 2025 | |
| F3778 | TYRO3 Antibody [L10H9] | Oct 13 2025 | |
| F4232 | GOT1 Antibody [J19L19] | Oct 13 2025 | |
| F1569 | TRF2 + TRF1 Antibody [H1E11] | Oct 13 2025 | |
| E1242 | Barbadin | バルバジン（Barbadin）は、新規かつ選択的なβ-アレスチン/β2-アダプチン相互作用阻害剤であり、β-アレスチン1に対するIC50値は19.1 μM、β-アレスチン2に対するIC50値は15.6 μMである。バルバジンは、代表的なβ2-アドレナリン受容体、V2-バソプレッシン受容体、およびアンジオテンシン-II 1型受容体のアゴニスト促進型エンドサイトーシスを阻害する。バルバジンはアポトーシスを誘導することができる。 | Oct 12 2025 |
| E6574 | NLRP3 | NLRP3/aim2-in-2 (compound 8) is a novel potent inhibitor exhibiting species-specific effects on NLRP3 and AIM2 inflammasome-dependent cell death, with an IC50 value of 0.2392 μM. | Oct 10 2025 |
| E6573 | Neuropathiazol | Neuropathiazol is a neuronal differentiation inducer that specifically promotes the neuronal differentiation of multipotent hippocampal neural progenitor cells. | Oct 10 2025 |
| E1955 | TNG348 | TNG348 is an orally bioavailable allosteric inhibitor targeting the ubiquitin-specific protease USP1. It selectively and potently blocks USP1 activity, preventing deubiquitination of proliferative PCNA and FANCD2, which disrupts DNA repair mechanisms. TNG348 demonstrates inhibitory effects against BRCA1/2-mutated and homologous recombination-deficient (HRD) breast and ovarian cancers . | Oct 10 2025 |
| E6596 | LAP | LAP（リチウムフェニル - 2,4,6 - トリメチルベンゾイルホスフィネート）はラジカル開始剤です。バイオプリンティング条件下でLAPによって生成されるラジカルは、潜在的に細胞毒性および変異原性を有します。さらに、LAPの濃度は3D印刷スキャフォールドの機械的強度に影響を与えます。一般に、硬化に使用されるLAPの濃度範囲は0.05％ - 1％です。0.1％の濃度で生成される弾性率が最も高く、機械的特性が向上し、優れた生体適合性を備えています。 | Sep 29 2025 |
| E6514 | BI033 | BI033 is a selective inhibitor of BTB and CNC homology 1 (BACH1) specifically binds to BACH1's N-terminal with a Kd of 9.0 uM. It disrupts the BACH1–HDAC1 interaction, enhances H3K27 acetylation at BACH1 target genes, and upregulates angiogenic genes, suggesting its therapeutic potential for myocardial infarction and ischemic vascular disease. | Sep 29 2025 |
| E1829 | Calderasib (MK-1084) | Calderasib (MK-1084) is a selective KRAS G12C inhibitor demonstrating antitumor efficacy. It can be utilized as monotherapy or in combination with pembrolizumab () for oncology research. | Sep 25 2025 |
| E7074 | Sulfo-NHS-LC-Biotin sodium | Sulfo-NHS-LC-Biotin sodium is a biotinylated amine-reactive ester compound that cannot cross the intact blood-retinal barrier. This reagent serves as a useful tool for evaluating vascular permeability in both cerebral and retinal vasculature. | Sep 24 2025 |
| E5854 | XYD049 | XYD049 (compound 7d) is a CRBN-based molecular glue targeting GSPT1 (DC50=19 nM), applicable for studying MYC-driven castration-resistant prostate cancer (CRPC). It demonstrates potent growth inhibition of 22Rv1 cells (IC50=7 nM) and exhibits in vivo antitumor activity. XYD049 downregulates CRPC-associated oncogenes (AR, AR-v7, PSA, c-Myc) in 22Rv1 cells. Structurally, it consists of: 1) a molecular glue linker (NH2-C5-NH-Boc), 2) a CRBN-recruiting E3 ligase ligand (Thalidomide 4-fluoride), and 3) a GSPT1-targeting moiety (GSPT1 ligand-1). The E3 ligase ligand-linker combination forms conjugate 158. | Sep 24 2025 |
| E1968 | BBO-8520 | BBO-8520 is a covalent small molecule inhibitor that selectively targets KRAS G12C with high oral bioavailability. It functions as both a KRAS G12C (OFF) inhibitor and a blocker of KRAS G12C (ON) signaling. The compound inhibits cellular proliferation by binding to GTP-bound KRAS G12C (ON), thereby preventing RAS-RAF1 interaction and promoting the transition to the inactive (OFF) state . | Sep 24 2025 |
| E6407 | CD2665 | CD2665 is an orally bioavailable selective antagonist of RAR-β and RAR-γ, exhibiting dissociation constants (Kd) of 306 nM for RAR-β and 110 nM for RAR-γ. | Sep 24 2025 |
- First Page
- Previous
-
- Next
- Last Page
納期 国内在庫品：受注日の翌日（15時までの受注分） ＊北海道、九州、沖縄への配送は受注日より２日以上 を要する場合あり 海外在庫品：受注後１〜２週間